Abstract
Colony stimulating factor 1 (CSF-1), a major regulator of the mononuclear phagocytic lineage, is expressed in more than 70% of human breast cancers and its expression is correlated with poor prognosis. Studies of CSF-1 null mutant mice demonstrated that CSF-1 plays an important role in normal mammary ductal development as well as in mammary tumor progression to metastasis. CSF-1 regulates these processes through the recruitment and regulation of macrophages, cells that become associated with mammary tumors and the terminal end buds at the end of the growing ducts. This phenomenon suggests that the tumors subvert normal developmental processes to allow invasion into the surrounding stroma, a process that gives the tumor access to the vasculature and consequently the promotion of metastasis. In addition, soluble CSF-1 secreted from the tumor acts to divert antitumor macrophage responses and suppresses the differentiation of mature tumor-antigen-presenting dendritic cells. This review discusses these observations in detail and attempts to fit them into a larger picture of CSF-1 and macrophage action in the regulation of normal mammary gland development and tumor progression.
Similar content being viewed by others
REFERENCES
J. M. Williams and C. W. Daniel (1983). Mammary ductal elon-gation: Differentiation of myoepithelium and basal lamina during branching morphogenesis. Dev.Biol. 97: 274–290.
M. C. Neville, D. Medina, J. Monks, and R. C. Hovey (1998). The mammary fat pad. J.Mam.Gland Biol.Neoplasia 3: 109–116.
V. Gouon-Evans, M. E. Rothenberg, and J. W. Pollard (2000). Postnatal mammary gland development requires macrophages and eosinophils. Development 127: 2269–2282.
M. A. Chrenek, P. Wong, and V. M. Weaver (2001). Tumour–stromal interactions. Integrins and cell adhesions as modu-lators of mammary cell survival and transformation. Breast Cancer Res. 3: 224–229.
G. B. Silberstein (2001). Tumour–stromal interactions. Role of the stroma in mammary development. Breast Cancer Res. 3: 218–223.
C. O'sullivan and C. E. Lewis (1994). Tumour-associated leucocytes: Friends or foes in breast carcinoma. J.PathoL. 172: 229–235.
K. Elgert, D. Alleva, and D. Mullins (1998). Tumor-induced immune dysfunction: The macrophage connection. J.Leukoc. Biol. 64: 275–290.
E. R. Stanley (1994). Colony stimulating factor-1 (macrophage colony stimulating factor). In A. W. Thomson (eds.), The Cytokine Handbook, Academic Press, San Diego, pp. 387–418.
S. M. Scholl, P. Crocker, R. Tang, P. Pouillart, and J. W. Pollard (1993). Is colony stimulating factor-1 a key mediator in breast cancer invasion and metastasis? Mol.Carcinog. 7: 207–211.
E. Y. Lin, A. V. Nguyen, R. G. Russell, and J. W. Pollard (2001). Colony-stimulating factor 1 promotes progression of mam-mary tumors to malignancy. J.Exp.Med. 193: 727–740.
S. W. Morris, M. D. Valentine, D. N. Shapiro, J. E. Sublett, L. L. Deaven, J. T. Foust, W. M. Roberts, D. P. Cerretti, and A. T. Look (1991). Reassignment of the human CSF1 gene to chromosome 1p13–p21. Blood 78: 2013–2020.
S. Gisselbrecht, B. Sola, S. Fichelson, D. Bordereau, P. Tambourin, M. G. Malter, D. Simon, and J.-L. Guenet (1989). The murine M-CSF gene is localized on chromosome 3. Blood 73: 1742–1746.
E. S. Kawasaki and M. B. Ladner (1990). Molecular biology of macrophage colony stimulating factor. In T. M. Dexter, J. M. Garland, and N. G. Testa (eds.), Colony Stimulating Factors: Molecular and Cellular Biology, Marcel Dekker, New York, pp. 155–176.
J. W. Pollard and E. R. Stanley (1996). Pleiotropic roles for CSF-1 in development defined by the mouse mutation os-teopetrotic (op). Adv.Dev.Biochem. 4: 153–193.
C. J. Sherr, C. W. Rettenmier, R. Sacca, M. S. Roussel, A. T. Look, and E. R. Stanley (1985). The c-fms proto-oncogene product is related to the receptor for the mononuclear phago-cyte growth factor, CSF-1. Cell 41: 665–676.
C. J. Sherr (1990). Colony stimulating factor-1 receptor. Blood 75: 1–12.
X. F. Csar, N. J. Wilson, K. A. McMahon, D. C. Marks, T. L. Beecroft, A. C. Ward, G. A. Whitty, V. Kanangasun-darum, and J. A. Hamilton (2001). Proteomic analysis of macrophage differentiation. p46/52(Shc) Tyrosine phospho-rylation is required for CSF-1-mediated macrophage differ-entiation. J.Biol.Chem. 276: 26211–26217.
R. J. Tushinski, I. T. Oliver, L. J. Guilbert, P. W. Tynan, J. R. Warner, and E. R. Stanley (1982). Survival of mononuclear phagocytes depends on a lineage-specific growth factor that the differentiated cells selectively destroy. Cell 28: 71–81.
E. R. Stanley, L. J. Guilbert, R. J. Tushinski, and S. H. Bartelmez (1983). CSF-1–a mononuclear phagocyte lineage-specific hemopoietic growth factor. J.Cell.Biochem. 21: 151–159.
S. E. Webb, J. W. Pollard, and G. E. Jones (1996). Direct ob-servation and quantification of macrophage chemoattraction to the growth factor CSF-1. J.Cell Sci. 109: 793–803.
C. W. Rettenmier and C. J. Sherr (1989). The mononuclear phagocyte colony-stimulating factor (CSF-1, M-CSF). Hema-tol. Oncol.Clin.North Am. 3: 479–493.
R.-P. Ryseck, H. MacDonald-Bravo, and R. Bravo (1991). The macrophage-colony stimulating factor gene is a growth factor-inducible immediate early gene in fibroblasts. N.Biol. 3: 151–157.
G. R. Ryan, X. M. Dai, M. G. Dominguez, W. Tong, F. Chuan, O. Chisholm, R. G. Russell, J. W. Pollard, and E. R. Stanley (2001). Rescue of the colony-stimulating factor 1 (CSF-1)-nullizygous mouse (Csf1 op /Csf1 op) phenotype with a CSF-1 transgene and identification of sites of local CSF-1 synthesis. Blood 98: 74–84.
R. Felix, W. Hofstetter, A. Wetterwald, M. G. Cecchini, and H. Fleisch (1994). Role of colony-stimulating factor-1 in bone metabolism. J.Cell.Biochem. 55: 340–349.
P. Roth and E. R. Stanley (1992). The biology of CSF-1 and its receptor. Curr.Top.Microbiol.Immunol. 181: 141–147.
W. Wiktor-Jedrzejczak, A. Bartocci, A. W. Ferrante Jr., A. Ahmed-Ansari, K. W. Sell, J. W. Pollard, and E. R. Stanley (1990). Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc. Natl.Acad.Sci.U.S.A. 87: 4828–4832.
M. G. Cecchini, M. G. Dominguez, S. Mocci, A. Wetterwald, R. Felix, H. Fleisch, O. Chisholm, W. Hofstetter, J. W. Pollard, and E. R. Stanley (1994). Role of colony stimulating factor-1 in the establishment and regulation of tissue macrophages during postnatal development of the mouse. Development 120: 1357–1372.
W. Wiktor-Jedrzejczak and S. Gordon (1996). Cytokine reg-ulation of the macrophage (MÁ) system studied using the colony stimulating factor-1-deficient op/op mouse. Physiol. Rev. 76: 927–947.
M. Naito, S. Hayashi, H. Yoshida, S. Nishikawa, L. D. Shultz, and K. Takahashi (1991). Abnormal differentiation of tissue macrophage populations in “osteopetrosis” (op) mice defec-tive in the production of macrophage colony-stimulating fac-tor. Am.J.Pathol. 139.
M. D. Witmer-Pack, D. A. Hughes, G. Schuler, L. Lawson, A. McWilliam, K. Inaba, R. M. Steinman, and S. Gordon (1993). Identification of macrophages and dendritic cells in the osteopetrotic (op/op) mouse. J.Cell Sci. 104: 1021–1029.
I. Guleria and J. W. Pollard (2001). Aberrant macrophage and neutrophil population dynamics and impaired Th1 response to Listeria monocytogenes in colony-stimulating factor 1-de-ficient mice. Infect.Immun. 69: 1795–1807.
X. Dai, G. R. Ryan, A. J. Hapel, M. G. Dominguez, R. G. Russell, S. Kapp, V. Sylvestre, and E. R. Stanley (2002). Tar-geted disruption of the mouse CSF-1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primititive progenitor cell frequencies and reproductive de-fects. Blood 99: 111–120.
J. W. Pollard (1997). Role of colony-stimulating factor-1 in reproduction and development. Mol.Reprod.Dev. 46: 54–61.
P. E. Cohen, K. Nishimura, L. Zhu, and J. W. Pollard (1999). Macrophages: Important accessory cells for reproductive function. J.Leukoc.Biol. 66: 765–772.
I. Guleria and J. W. Pollard (2000). The trophoblast is a com-ponent of the innate immune system during pregnancy. Nat. Med. 6: 589–593.
B. M. Kacinski (1997). CSF-1 and its receptor in breast carci-nomas and neoplasms of the female reproductive tract. Mol. Reprod.Dev. 46: 71–74.
S. Ramakrishnan, F. J. Xu, S. J. Brandt, J. E. Niedel, R. C. Bast Jr., and E. L. Brown (1989). Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. J.Clin.Invest. 83: 921–926.
G. Baiocchi, J. J. Kavanagh, M. Talpaz, J. T. Wharton, J. U. Gutterman, and R. Kurzrock (1991). Expression of the macrophage colony-stimulating factor and its receptor in gy-necologic malignancies. Cancer 67: 990–996.
H. O. Smith, P. S. Anderson, D. Y. K. Kuo, G. L. Goldberg, C. L. DeVictoria, C. A. Boocock, J. G. Jones, C. D. Runowicz, E. R. Stanley, and J. W. Pollard (1995). The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma. Clin.Cancer Res. 1: 313–325.
B. M. Kacinski (1995). CSF-1 and its receptor in ovarian, en-dometrial and breast cancer. Ann.Med. 27: 79–85.
F. V. Price, S. K. Chambers, J. T. Chambers, M. L. Carcangiu, P. E. Schwartz, E. I. Kohorn, E. R. Stanley, and B. M. Kacinski (1993). Colony-stimulating factor-1 in primary ascites of ovar-ian cancer is a significant predictor of survival. Am.J.Obstet. Gynecol. 168: 520–527.
A. Hakala, B. M. Kacinski, E. R. Stanley, E. I. Kohorn, U. Puistola, J. Risteli, L. Risteli, C. Thomas, and A. Kauppila (1995). Macrophage colony-stimulating factor 1, a clinically useful tumor marker in endometrial adenocarcinoma: Com-parison with CA 125 and the aminoterminal propeptide of type III procollagen. Am.J.Obstet.Gynecol. 173: 112–119.
S. M. Scholl, C. Pallud, F. Beuvon, K. Hacene, E. R. Stanley, L. R. Rohrschneider, R. Tang, P. Pouillart, and R. Lidereau (1994). Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked in-flammatory cell infiltrates and prognosis. J.Natl.Cancer Inst. 86: 120–126.
E. Sapi and B. M. Kacinski (1999). The role of CSF-1 in normal and neoplastic breast physiology. Proc.Soc.Exp.Biol.Med. 220: 1–8.
M. G. Maher, E. Sapi, B. Turner, A. Gumbs, P. L. Perrotta, D. Carter, B. M. Kacinski, and B. G. Haffty (1998). Prognostic significance of colony-stimulating factor receptor expression in ipsilateral breast cancer recurrence. Clin.Cancer Res. 4: 1851–1856.
R. S. McDermott, L. Deneux, V. Mosseri, J. Vedrenne, K. Clough, A. Fourquet, J. Rodriguez, J. M. Cosset, X. Sastre, P. Beuzeboc, P. Pouillart, and S. M. Scholl (2002). Circulating macrophage colony stimulating factor as a marker of tumour progression. Eur Cytokine Netw. 13: 121–127.
E. Sapi, M. B. Flick, S. Rodov, M. Gilmore-Hebert, M. Kelley, S. Rockwell, and B. M. Kacinski (1996). Independent regulation of invasion and anchorage-independent growth by different autophosphorylation sites of the macrophage colony-stimulating factor 1 receptor. Cancer Res. 56: 5704–5712.
E. Sapi, M. B. Flick, S. Rodov, and B. M. Kacinski (1998). Ets-2 transdominant mutant abolishes anchorage-independent growth and macrophage colony-stimulating factor-stimulated invasion by BT20 breast carcinoma cells. Cancer Res. 58: 1027–1033.
S. J. Langer, D. M. Bortner, M. F. Roussel, C. J. Sherr, and M. C. Ostrowski (1992). Mitogenic signaling by colony-stimulating factor 1 and ras is suppressed by the ets-2 DNA-binding domain and restored by myc overexpression. Mol. Cell.Biol. 12: 5355–5362.
A. E. Filderman, A. Bruckner, B. M. Kacinski, N. Deng, and H. G. Remold (1992). Macrophage colony-stimulating factor (CSF-1) enhances invasiveness in CSF-1 receptor-positive car-cinoma cell lines. Cancer Res. 53: 3661–3666.
P. M. Kelly, R. S. Davison, E. Bliss, and J. O. McGee (1988). Macrophages in human breast disease: A quantitative im-munohistochemical study. Br.J.Cancer 57: 174–177.
R. D. Leek, A. L. Harris, and C. E. Lewis (1994). Cytokine networks in solid human tumors: Regulation of angiogenesis. J.Leukoc.Biol. 56: 423–435.
F. Balkwill and A. Mantovani (2001). Inflammation and can-cer: Back to Virchow? Lancet 357: 539–545.
A. Mantovani, B. Bottazzi, F. Colotta, S. Sozzani, and L. Ruco (1992). The origin and function of tumor-associated macrophages. Immunol.Today 13: 265–270.
I. L. Bonta and S. Ben-Efraim (1993). Involvement of in-flammatory mediators in macrophage antitumor activity. J.Leukoc.Biol. 54: 613–626.
R. B. Herberman, H. T. Holden, J. Y. Djeu, T. R. Jerrells, L. Varesio, A. Tagliabue, S. L. White, J. R. Oehler, and J. H. Dean (1979). Macrophages as regulators of immune responses against tumors. Adv.Exp.Med.Biol. 361–379.
B. al-Sarireh and O. Eremin (2000). Tumour-associated macrophages (TAMS): Disordered function, immune sup-pression and progressive tumour growth. J.R. Coll.Surg. Edinb. 45: 1–16.
R. S. Kerbel (2000). Tumor angiogenesis: Past, present and the near future. Carcinogenesis. 21: 505–515.
J. S. Lewis, R. J. Landers, J. C. Underwood, A. L. Harris, and C. E. Lewis (2000). Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J.Pathol. 192: 150–158.
M. Lingens (2001). Role of leukocytes and endothelial cells in the development of angiogenesis in inflammation and wound healing. Arch.Pathol.Lab.Med. 125.
L. Turner, C. Scotton, R. Negus, and F. Balkwill (1999). Hypoxia inhibits macrophage migration. Eur.J.Immunol. 29: 2280–2287.
H. J. Knowles and A. L. Harris (2001). Hypoxia and tumouri-genesis. Breast Cancer Res. 3: 318–322.
C. E. Lewis, R. Leek, A. Harris, and J. O. McGee (1995). Cy-tokine regulation of angiogenesis in breast cancer: The role of tumor-associated macrophages. J.Leukoc.Biol. 57: 747–751.
R. D. Leek, C. E. Lewis, R. Whitehouse, M. Greenall, J. Clarke, and A. L. Harris (1996). Association of macrophage infiltra-tion with angiogenesis and prognosis in invasive breast carci-noma. Cancer Res. 56: 4625–4629.
K. Engels, S. B. Fox, R. M. Whitehouse, K. C. Gatter, and A. L. Harris (1997). Up-regulation of thymidine phosphorylase ex-pression is associated with a discrete pattern of angiogenesis in ductal carcinomas in situ of the breast. J.Pathol. 182: 414–420.
C. T. Guy, R. D. Cardiff, and W. J. Muller (1992). Induction of mammary tumors by expression of polyomovirus middle T oncogenes: A transgenic mouse mode of a metastatic dis-ease. Mol.Cell.Biol. 12: 954–961.
M. R. Jadus, C. C. Williams, M. D. Avina, M. Ly, S. Kim, Y. Liu, R. Narasaki, C. A. Lowell, and H. T. Wepsic (1998). Macrophages kill T9 glioma tumor cells bearing the membrane isoform of macrophage colony stimulating fac-tor through a phagocytosis-dependent pathway. J.Immunol. 160: 361–368.
M. R. Jadus, M. C. Irwin, M. R. Irwin, R. D. Horansky, S. Sekhon, K. A. Pepper, D. B. Kohn, and H. T. Wepsic (1996). Macrophages can recognize and kill tumor cells bearing the membrane isoform of macrophage colony-stimulating factor. Blood 87: 5232–5241.
M. R. Graf, M. R. Jadus, J. C. Hiserodt, H. T. Wepsic, and G. A. Granger (1999). Development of systemic immunity to glioblastoma multiforme using tumor cells genetically en-gineered to express the membrane-associated isoform of macrophage colony-stimulating factor. J.Immunol. 163: 5544–5551.
C. C. Williams, H. Trinh, T. V. Tran, Q. Dan, R. Sanchez, C. Delgado, Y. Chen, B. Sippel, E. W. Jeffes, H. T. Wepsic, and M. R. Jadus (2001). Membrane macrophage colony-stimulating factor on MADB106 breast cancer cells does not activate cytotoxic macrophages but immunizes rats against breast cancer. Mol.Ther. 3: 216–224.
J. E. Ohm and D. P. Carbone (2001). VEGF as a mediator of tumor-associated immunodeficiency. Immunol.Res. 23: 263–272.
J. Banchereau, F. Briere, C. Caux, J. Davoust, S. Lebecque, Y. J. Liu, B. Pulendran, and K. Palucka (2000). Immuno-biology of dendritic cells. Annu.Rev.Immunol. 18: 767–811.
B. Almand, J. R. Resser, B. Lindman, S. Nadaf, J. I. Clark, E. D. Kwon, D. P. Carbone, and D. I. Gabrilovich (2000). Clin-ical significance of defective dendritic cell differentiation in cancer. Clin.Cancer Res. 6: 1755–1766.
C. Menetrier-Caux, G. Montmain, M. C. Dieu, C. Bain, M. C. Favrot, C. Caux, and J. Y. Blay (1998). Inhibition of the differentiation of dendritic cells from CD34( C ) progenitors by tumor cells: Role of interleukin-6 and macrophage colony-stimulating factor. Blood 92: 4778–4791.
C. Menetrier-Caux, M. C. Thomachot, L. Alberti, G. Montmain, and J. Y. Blay (2001). IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells. Cancer Res. 61: 3096–3104.
P. A. Andreasen, R. Egelund, and H. H. Petersen (2000). The plasminogen activation system in tumor growth, invasion, and metastasis. Cell.Mol.Life Sci. 57: 25–40.
J. A. Foekens, H. A. Peters, M. P. Look, H. Portengen, M. Schmitt, M. D. Kramer, N. Brunner, F. Janicke, M. E. Meijer-van Gelder, S. C. Henzen-Logmans, W. L. van Putten, and J. G. Klijn (2000). The urokinase system of plasminogen ac-tivation and prognosis in 2780 breast cancer patients. Cancer Res. 60: 636–643.
S. A. Rabbani and A. P. Mazar (2001). The role of the plas-minogen activation system in angiogenesis and metastasis. Surg.Oncol.Clin.N.Am. 10: 393–415.
S. Kennedy, M. J. Duffy, C. Duggan, C. Barnes, R. Rafferty, and M. D. Kramer (1998). Semi-quantitation of urokinase plas-minogen activator and its receptor in breast carcinomas by immunocytochemistry. Br.J.Cancer. 77: 1638–1641.
R. Hildenbrand, W. Glienke, V. Magdolen, H. Graeff, H. J. Stutte, and M. Schmitt (1998). Urokinase receptor localiza-tion in breast cancer and benign lesions assessed by in situ hy-bridization and immunohistochemistry. Histochem.Cell.Biol. 110: 27–32.
R. Hildenbrand, G. Wolf, B. Bohme, U. Bleyl, and A. Steinborn (1999). Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal car-cinoma in situ, breast cancer, and resident macrophages of normal breast tissue. J.Leukoc.Biol. 66: 40–49.
S. B. Fox, M. Taylor, J. Grondahl-Hansen, S. Kakolyris, K. C. Gatter, and A. L. Harris (2001). Plasminogen activa-tor inhibitor-1 as a measure of vascular remodelling in breast cancer. J.Pathol. 195: 236–243.
L. F. Fowles, K. J. Stacey, D. Marks, J. A. Hamilton, and D. A. Hume (2000). Regulation of urokinase plasminogen activator gene transcription in the RAW264 murine macrophage cell line by macrophage colony-stimulating factor (CSF-1) is de-pendent upon the level of cell-surface receptor. Biochem.J. 347(Part 1): 313–320.
K. J. Stacey, L. F. Fowles, M. S. Colman, M. C. Ostrowski, and D. A. Hume (1995). Regulation of urokinase-type plas-minogen activator gene transcription by macrophage colony-stimulating factor. Mol.Cell.Biol. 15: 3430–3441.
X. H. Pei, Y. Nakanishi, K. Takayama, F. Bai, and N. Hara (1999). Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the in-vasive capacity of human lung cancer cells. Br.J.Cancer 79: 40–46.
L. D. Yee and L. Liu (2000). The constitutive production of colony stimulating factor 1 by invasive human breast cancer cells. Anticancer Res. 20: 4379–4383.
H. Bando and M. Toi (2000). Tumor angiogenesis, macrophages, and cytokines. Adv.Exp.Med.Biol. 476: 267–284.
B. Dankbar, T. Padro, R. Leo, B. Feldmann, M. Kropff, R. M. Mesters, H. Serve, W. E. Berdel, and J. Kienast (2000). Vas-cular endothelial growth factor and interleukin-6 in paracrine tumor–stromal cell interactions in multiple myeloma. Blood 95: 2630–2636.
C. Frelin, A. Ladoux, and G. D'Angelo (2000). Vascular en-dothelial growth factors and angiogenesis. Ann.Endocrinol. (Paris) 61: 70–74.
H. Saji, M. Koike, T. Yamori, S. Saji, M. Seiki, K. Matsushima, and M. Toi (2001). Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 92: 1085–1091.
D. Toomey, C. Condron, Q. D. Wu, E. Kay, J. Harmey, P. Broe, C. Kelly, and D. Bouchier-Hayes (2001). TGF-beta1 is elevated in breast cancer tissue and regulates nitric oxide production from a number of cellular sources during hypoxia re-oxygenation injury. Br.J.Biomed.Sci. 58: 177–183.
L. L. Thomsen and D. W. Miles (1998). Role of nitric oxide in tumour progression: Lessons from human tumours. Cancer Metastasis Rev. 17: 107–118.
L. C. Jadeski and P. K. Lala (1999). Nitric oxide synthase inhi-bition by N(G)-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am.J.Pathol. 155: 1381–1390.
R. Rajan, R. Vanderslice, S. Kapur, J. Lynch, R. Thompson, and D. Djakiew (1996). Epidermal growth factor (EGF) pro-motes chemomigration of a human prostate tumor cell line, and EGF immunoreactive proteins are present at sites of metastasis in the stroma of lymph nodes and medullary bone. Prostate 28: 1–9.
G. D. Roodman (2001). Biology of osteoclast activation in cancer. J.Clin.Oncol. 19: 3562–3571.
H. Kodama, M. Nose, S. Niida, and A. Yamasaki (1991). Es-sential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. J.Exp. Med. 173: 1291–1294.
A. Grey, Y. Chen, I. Paliwal, K. Carlberg, and K. Insogna (2000). Evidence for a functional association between phos-phatidylinositol 3-kinase and c-src in the spreading response of osteoclasts to colony-stimulating factor-1. Endocrinology 141: 2129–2138.
N. C. Hunt, Y. Fujikawa, A. Sabokbar, I. Itonaga, A. Harris, and N. A. Athanasou (2001). Cellular mechanisms of bone resorption in breast carcinoma. Br.J.Cancer 85: 78–84.
J. M. Quinn, J. O. McGee, and N. A. Athanasou (1998). Human tumour-associated macrophages differentiate into osteoclas-tic bone-resorbing cells. J.Pathol. 184: 31–36.
A. T. Mancino, V. S. Klimberg, M. Yamamoto, S. C. Manolagas, and E. Abe (2001). Breast cancer increases osteoclastogene-sis by secreting M-CSF and upregulating RANKL in stromal cells. J.Surg.Res. 100: 18–24.
J. W. Pollard and L. Henninghausen (1994). Colony stim-ulating factor-1 is required for mammary gland develop-ment during pregnancy. Proc.Natl.Acad.Sci.U.S.A. 91: 9312–9316.
P. E. Cohen, L. Zhu, and J. W. Pollard (1997). The absence of CSF-1 in osteopetrotic (csfm op /csfm op) mice disrupts estrous cycles and ovulation. Biol.Reprod. 56: 110–118.
A. V. Nguyen and J. W. Pollard (2002). Colony stimulating factor-1 is required to recruit macrophages into the mam-mary gland to facilitate mammaryductal outgrowth. Dev.Biol. 247: 11–25.
R. C. Humphreys, M. Krajewska, S. Krnacik, R. Jaeger, H. Weiher, S. Krajewski, J. C. Reed, and J. M. Rosen (1996). Apoptosis in the terminal endbud of the murine mammary gland: A mechanism of ductal morphogenesis. Development 122: 4013–4022.
L. M. Coussens, C. L. Tinkle, D. Hanahan, and Z. Werb (2000). MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103: 481–490.
L. M. Coussens and Z. Werb (2001). Inflammatory cells and cancer: Think different! J.Exp.Med. 193: F23–26.
H. Kuper, H. O. Adami, and D. Trichopoulos (2000). Infections as a major preventable cause of human cancer. J.Intern.Med. 248: 171–183.
L. A. Garcia Rodriguez and Huerta-Alvarez, C. (2001). Re-duced risk of colorectal cancer among long-term users of as-pirin and nonaspirin nonsteroidal anti-inflammatory drugs. Epidemiology 12: 88–93.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lin, E.Y., Gouon-Evans, V., Nguyen, A.V. et al. The Macrophage Growth Factor CSF-1 in Mammary Gland Development and Tumor Progression. J Mammary Gland Biol Neoplasia 7, 147–162 (2002). https://doi.org/10.1023/A:1020399802795
Issue Date:
DOI: https://doi.org/10.1023/A:1020399802795